Why Medicxi invested in Evotec’s DNA damage repair spinout

The opportunity to get into the DNA damage repair space was enough for Medicxi to bend its asset-centric rule and lead the €30 million ($33.7 million) series A round for Evotec spinout Breakpoint.

Medicxi's Jon Edwards told BioCentury that the firm had been evaluating the DNA damage repair (DDR) space for a while, with Breakpoint Therapeutics GmbH (Hamburg, Germany) presenting the best investment opportunity to get in...